Nexgenia
Seattle, US · Founded 2011 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
RM
Ron MyersExecutive
Board
SG
Steven GillisBoard directorManaging Director, ARCH Venture Partners at The W Fund
CP
Charles P. WaiteBoard director
MS
Martin SimonettiBoard director
SP
Stewart ParkerBoard director
DU
David UrdalBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.1M disclosed across 4 of 5 rounds · 2014–2018
▶$119.1KraisedMay 2018 · 14 investors · BiotechnologyRule 506(b)
▶$119.1KraisedMay 2018 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven GillisDirector
- Stewart ParkerDirector
- Ron MyersExecutive Officer, Director
- David UrdalDirector
- Martin SimonettiDirector
- Charles P. WaiteDirector
- Offering amount
- $250K
- Amount sold
- $119.1K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9KofferedApr 2017 · 1 investors · BiotechnologyRule 506(b)
▶$1.9KofferedApr 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron MyersExecutive Officer, Director
- Charles P. WaiteDirector
- David UrdalDirector
- Steven GillisDirector
- Stewart ParkerDirector
- Martin SimonettiDirector
- Offering amount
- $1.9K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedAug 2016 · 15 investors · BiotechnologyRule 506(b)
▶$1.9MraisedAug 2016 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin SimonettiDirector
- Charles P. WaiteDirector
- David UrdalDirector
- Stewart ParkerDirector
- Ron MyersExecutive Officer, Director
- Steven GillisDirector
- Offering amount
- $2M
- Amount sold
- $1.9M
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJun 2015 · 9 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJun 2015 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin SimonettiDirector
- Stewart ParkerDirector
- David UrdalDirector
- Ron MyersExecutive Officer, Director
- Steven GillisDirector
- Charles P. WaiteDirector
- Offering amount
- $3.5M
- Amount sold
- $1.6M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$500KraisedOct 2014 · 2 investors · BiotechnologyRule 506(b)
▶$500KraisedOct 2014 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stewart ParkerDirector
- David UrdalDirector
- Ron MyersExecutive Officer, Director
- Martin SimonettiDirector
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapMission BioCapital Platinum Program Holdings LLC6 shared keywordsMission BioCapital is an early-stage venture capital firm that provides capital and shared lab space to life science startups, supporting founders from initial experiments through to the clinic. Founded in 2009, it invests in early-stage life science companies and is currently deploying its fifth fund.
Globaldata4 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Wugen4 shared keywordsAllotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
TellBio3 shared keywordsTellBio is a development-stage biotechnology company building the TellDx CTC System, a microfluidic diagnostic platform that isolates and detects circulating tumor cells (CTCs) to detect and monitor cancer progression, along with a therapeutics arm developing anti-cancer drugs based on CTC research. Its CTC isolation technology is exclusively licensed from Massachusetts General Hospital and is deployed as a research tool at centers of excellence.
Immunovant3 shared keywordsImmunovant is a clinical-stage biopharmaceutical company developing treatments for people with autoimmune diseases, with a focus on therapies targeting the FcRn receptor. It advances a pipeline of candidates across multiple therapeutic areas through clinical trials.
Companies competing with Nexgenia for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $232.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $196.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who are Nexgenia's investors?
- Nexgenia's investors include The W Fund.
- How much funding has Nexgenia raised?
- Nexgenia has disclosed $4.1M raised across 4 of its 5 known rounds.
- Where is Nexgenia headquartered?
- Nexgenia is headquartered in Seattle, US.